We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mitochondrial Breakdown Promotes Death of Hypoxic Cells

By LabMedica International staff writers
Posted on 30 Nov 2011
Combining and breaking down of mitochondria are linked to how cells respond to changes in their environment. More...
A recent study has identified a molecular pathway critical to this process.

Investigators at the Sanford-Burnham Medical Research Institute (La Jolla, CA; USA) exposed cardiomyocyte cultures to low oxygen concentrations (hypoxia) that were similar to conditions found in the heart muscle following a heart attack.

They reported in the November 18, 2011, issue of the journal Molecular Cell that hypoxia-induced fission of mitochondrial membranes, dependent on availability of the mitochondrial scaffolding protein AKAP121.

Mitochondrial fission, which caused the heart cells to die, was stimulated when the ubiquitin ligase Siah2 reduced availability of AKAP121. Siah2 gene is a member of the seven in absentia homolog (Siah) family of proteins. The enzyme is an E3 ligase and is involved in ubiquitination and proteasome-mediated degradation of specific proteins. The activity of this ubiquitin ligase has been implicated in regulating cellular response to hypoxia.

Suppressing the activity of Siah2 in hypoxic cells or in mice increased AKAP121 levels, which reduced mitochondrial fission and resulted in death of fewer heart cells. Under hypoxic conditions, Siah2-deficient mice fared better than their normal counterparts did.

“Our work reveals key aspects to controlling mitochondrial dynamics in response to low oxygen tension,” said senior author Dr. Ze'ev A. Ronai, associate director the cancer center at the Sanford-Burnham Medical Research Institute. “By manipulating mitochondrial dynamics, we can help cells adapt to ischemic conditions in a way that might translate into new treatment options for patients who have experienced a heart attack.”

Research efforts are now focused on the pursuit of chemical compounds to inhibit Siah2 that can be further developed into new therapies to prevent or reverse cardiac damage.

Related Links:

Sanford-Burnham Medical Research Institute








Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.